Register your Account

Sign Up with us and Enjoy!
User name Email First Name Last Name Contact info

A password will be e-mailed to you.

Healthcare Gainers (KERX, AET, ACAD, CI, ILMN)

NEW YORK, October 12, 2012 (MESHPRESS) –, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:-

Keryx Biopharmaceuticals(NASDAQ:KERX) stock increased 6.83% to $2.97 in the last trading session. Keryx stock had its price target boosted by Ladenburg Thalmann from $3.00 to $5.00 in a research report released yesterday. Ladenburg Thalmann currently has a buy rating on the stock.

Separately, analysts at Oppenheimer reiterated an outperform rating on shares of Keryx in a research note to investors on September 5.

Can KERX Extend Massive Gain? Find Out Here

Aetna Inc.(NYSE:AET) shares gained 3.34% and closed at $43.29 in yesterday’s session. The company received an award from America’s Health Insurance Plans, under funding provided through the Centers for Disease Control and Prevention (CDC), to offer a type 2 diabetes prevention program to Aetna beneficiaries in Texas. This 2012 Prevention and Public Health Fund cooperative agreement is part of a national effort to reduce the number of new cases of type 2 diabetes through the National Diabetes Prevention Program.

Can AET Extend Gain? Find Out Here

ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD) shares increased 2.94% and closed at $2.45 in the last trading session. Roth Capital believes that a recent article in the journal Schizophrenia Research could increase use of ACADIA’s pimavanserin as an off-label schizophrenia treatment. The firm thinks that changes made to the current study of the drug compared with previous studies should cause it to yield statistically significant results, and Roth maintains a $3 target and Buy rating on the shares.

How Should Investors Trade ACAD Now? Find Out Here

CIGNA Corporation(NYSE:CI) shares jumped 2.81% and closed at $50.14 in the last trading session. Zacks reissued their neutral rating on shares of CIGNA in a report released this week. Zacks currently has a $51.00 target price on the stock. Zacks’ analyst wrote that CIGNA Corp. reported second-quarter core earnings of $1.52 per share outpacing the Zacks Consensus Estimate by $0.09. Moreover, the results were up 3.4% year over year. They believe that Cigna is strongly poised to record earnings growth given a number of strategic investments undertaken.

Can CI Jump Again? Find Out Here

Illumina, Inc.(NASDAQ:ILMN) shares increased 2.23% to $52.23 in the last trading session. Illumina‘s stock had its “outperform” rating reiterated by equities research analysts at Credit Suisse in a research note issued to investors this month. They currently have a $55.00 price target on the stock.

Get Free Trend Analysis on To Know More About ILMN Here

About Cogo News has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.

Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities.  does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.



Related Press realease: